Global Oncology Precision Medicine Market Forecast 2029: Size, Share, and Competitive Landscape
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
#How Is The Oncology Precision Medicine Market Expected To Grow In Terms Of Size?#_x000D_
In recent years, there’s been a swift expansion in the size of the oncology precision medicine market. This is expected to rise from $110.90 billion in 2024 to $125.14 billion in 2025, marking a compound annual growth rate (CAGR) of 12.8%. Factors contributing to this growth during the historic period include an increase in cancer incidence, wider acceptance of targeted treatments, escalating investment in genomic research, enlargement of healthcare infrastructure, and heightened awareness regarding personalized medicine._x000D_
_x000D_
The market size of precision medicine in oncology is predicted to witness an accelerated expansion in the forthcoming years. The market is set to escalate to $201.40 billion by 2029, with a Compound Annual Growth Rate (CAGR) standing at 12.6%. This expansion during the projected period can be associated with the surging demand for non-intrusive cancer diagnostic methods, growing inclination towards personalized treatment measures, the increasing usage of companion diagnostics, constantly enlarging portfolio of precision oncology drugs, and a boom in clinical application of Artificial Intelligence tools. The forecast span will see trends such as advancement in liquid biopsy technology, next-generation sequencing innovations, progress in data analysis through Artificial Intelligence, R&D in biomarker discovery, and the merging of multi-omics in clinical oncology._x000D_
_x000D_
#Get A Free Sample Of The Report:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=25853&type=smp_x000D_
_x000D_
#What Market Forces Are Contributing To The Growth Of The Oncology Precision Medicine Market?#_x000D_
The increasing incidence of cancer is predicted to drive the expansion of the oncology precision medicine market. Cancer, a condition characterized by the uncontrollable growth and potential spread of abnormal cells, disrupts regular bodily operations. This escalating cancer trend is largely attributed to aging populations. Which is due to protracted life spans resulting in the accumulation of DNA mutations, reduced repair mechanisms, chronic inflammaging, a declining immune surveillance, and evolving tissue microenvironments that increasingly favour tumor development. Oncology precision medicine aids in personalizing cancer treatments by tailoring them to the distinct genetic profile of each tumor, enhancing efficiency and minimizing side effects. For instance, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, the number of anticipated new cancer cases in 2022, which stands at 20 million, is projected to soar by 77%, amounting to over 35 million cases by 2050. Consequently, the rising incidence of cancer is stimulating the growth of the oncology precision medicine market._x000D_
_x000D_
#How Is The Oncology Precision Medicine Market Segmented Across Key Categories?#_x000D_
The oncology precision medicine market covered in this report is segmented – _x000D_
_x000D_
1) By Product Type: Diagnostics, Therapeutics, Inhibitor Drugs, Monoclonal Antibodies, Cell And Gene Therapy, Antiviral And Anti-Retroviral Drugs_x000D_
2) By Technology: Genomics, Proteomics, Bioinformatics, Other Technologies_x000D_
3) By Biomarker Types: Genetic Biomarkers, Protein Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Other Biomarker Types_x000D_
4) By Applications: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer, Kidney Cancer, Liver Cancer, Bladder Cancer, Other Applications_x000D_
5) By End-Users: Hospitals, Diagnostic Laboratories, Research Institutions, Pharmaceutical Companies, Other End-Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Diagnostics: Companion Diagnostics, Molecular Diagnostics, Liquid Biopsy, Imaging Diagnostics, Next-Generation Sequencing Assays_x000D_
2) By Therapeutics: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)_x000D_
3) By Inhibitor Drugs: Tyrosine Kinase Inhibitors (TKIs), Poly ADP-Ribose Polymerase Inhibitors (PARP Inhibitors), Cyclin-Dependent Kinase 4 And 6 Inhibitors (CDK4/6 Inhibitors), B-Raf Proto-Oncogene Serine Or Threonine Kinase Inhibitors (BRAF Inhibitors), Mitogen-Activated Protein Kinase Kinase Inhibitors (MEK Inhibitors)_x000D_
4) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, Radiolabeled Antibodies_x000D_
5) By Cell And Gene Therapy: CAR-T Cell Therapies, T-Cell Receptor (TCR) Therapies, Tumor-Infiltrating Lymphocyte (TIL) Therapies, Oncolytic Viral Therapies, Gene Editing And Replacement Therapies_x000D_
6) By Antiviral And Anti-Retroviral Drugs: Reverse Transcriptase Inhibitors, Protease Inhibitors, Integrase Strand Transfer Inhibitors, Entry Inhibitors, Antiviral Agents Targeting Virus-Related Cancers_x000D_
_x000D_
#What Key Trends Are Driving Growth In The Oncology Precision Medicine Market?#_x000D_
Companies at the forefront of the oncology precision medicine market are concentrating on the evolution of novel solutions, like molecular tumor board initiatives, with the goal of fostering multidisciplinary cooperation and honing in on individualized treatment plans. Such molecular tumor boards consist of seasoned professionals well versed in dissecting complex genetic and molecular test outcomes to suggest bespoke cancer treatment methodologies. McKesson Corporation, an American healthcare services firm with a hub in information technology, for example, unveiled the Precision Care Companion initiative in April 2025. This initiative is designed to fortify biomarker-based cancer care by offering education, advancements in technology, and hands-on help to oncology practices. It amalgamates doctors, clinical staff, industry leaders, and pharmaceutical associates to establish a functioning collaborative setting that expedites the integration of sophisticated genomic testing and targeted treatments. This helps caregivers provide high-quality personalized cancer treatments and enhance patient wellbeing._x000D_
_x000D_
#Who Are The Major Stakeholders Operating In The Oncology Precision Medicine Market?#_x000D_
Major companies operating in the oncology precision medicine market are Roche Holding AG, Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, Gilead Sciences Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Inc., Agilent Technologies Inc., Illumina Inc., bioMérieux S.A., Bio-Rad Laboratories Inc., Exact Sciences Corporation, Almac Group Limited, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Pacific Biosciences of California Inc., Asuragen Inc., BGI Group, ANGLE plc. _x000D_
_x000D_
#Access The Complete Report Here:#_x000D_
_x000D_
#How Do Regional Dynamics Influence The Oncology Precision Medicine Market Performance?#_x000D_
North America was the largest region in the oncology precision medicine market in 2024. The regions covered in the oncology precision medicine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Customize Your Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=25853&type=smp_x000D_
_x000D_
Browse Through More Reports Similar to the Global Oncology Precision Medicine Market 2025, By The Business Research Company_x000D_
_x000D_
Clinical Oncology Next Generation Sequencing Global Market Report 2025_x000D_
_x000D_
Oncology Devices Global Market Report 2025_x000D_
https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report_x000D_
_x000D_
Oncology Biomarkers Global Market Report 2025_x000D_
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
